With all due respect to Mr. Schoenebaum and Mr. Werber, I think it’s grossly premature to label MRK as the #2 HCV player based on the pill count argument, which third-party payers don’t seem to care about.
I wouldn't paid much heed to Mr. Schoenebaum who stated that MRK can finish their PH3 trials in 6 months. lol.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.